Payment overview · 2025
General Payments
$840.57
44 reported records · 12 companies
Healthcare provider profile · identity verified
Anna Sullivan Bruton, ANP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · CLAYTON, NC · NPI 1023354024
Verified facts
What the public records show
CMS Open Payments records show Anna Sullivan Bruton, ANP-C received $840.57 in general payments during 2025 across 44 reported records.
ABBVIE INC. accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $251.40 | 29.9% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $153.40 | 18.2% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $122.21 | 14.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $83.67 | 9.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.83 | 7.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.43 | 4.9% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.66 | 3.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $25.61 | 3.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.09 | 2.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.39 | 2.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.73 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.15 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $840.57 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $138.09 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $125.66 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $122.21 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $119.71 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $113.31 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $91.43 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $83.67 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.84 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.84 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $41.43 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.43 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $28.54 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $27.74 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $25.61 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 107 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
107 | 16 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 444 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 394 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 367 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 322 | 67 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 317 | 39 |
| Omeprazole | Omeprazole | 313 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 310 | 77 |
| Alprazolam | Alprazolam | 280 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 279 | 66 |
| Furosemide | Furosemide | 270 | 62 |
| Lisinopril | Lisinopril | 252 | 65 |
| Metformin Hcl | Metformin Hcl | 225 | 58 |
| Potassium Chloride | Potassium Chloride | 205 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 203 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 200 | 38 |
| Oxycodone Hcl | Oxycodone Hcl | 200 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 44 |
| Losartan Potassium | Losartan Potassium | 169 | 44 |
| Trazodone Hcl | Trazodone Hcl | 157 | 43 |
| Simvastatin | Simvastatin | 154 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 147 | 27 |
| Tramadol Hcl | Tramadol Hcl | 147 | 28 |
| Montelukast Sodium | Montelukast Sodium | 131 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 128 | 26 |
| Meloxicam | Meloxicam | 127 | 34 |
| Allopurinol | Allopurinol | 125 | 26 |
| Celecoxib | Celecoxib | 125 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 121 | 22 |
| Carvedilol | Carvedilol | 117 | 26 |
| Eliquis | Apixaban | 117 | 23 |
| Ezetimibe | Ezetimibe | 113 | 25 |
| Mirtazapine | Mirtazapine | 112 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 108 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 25 |
| Ozempic | Semaglutide | 107 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 29 |
| Prednisone | Prednisone | 106 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 17 |
| Sertraline Hcl | Sertraline Hcl | 89 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 25 |
| Famotidine | Famotidine | 81 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 81 | 21 |
| Spironolactone | Spironolactone | 78 | 22 |
| Fluconazole | Fluconazole | 77 | 31 |
| Promethazine Hcl | Promethazine Hcl | 77 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 75 | 20 |
| Jardiance | Empagliflozin | 74 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 70 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | 13 |
| Glipizide | Glipizide | 65 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 23 |
| Bupropion Xl | Bupropion Hcl | 62 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 60 | 13 |
| Clonazepam | Clonazepam | 60 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | suppressed |
| Levofloxacin | Levofloxacin | 58 | 29 |
| Glimepiride | Glimepiride | 56 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | suppressed |
| Nystatin | Nystatin | 55 | 16 |
| Torsemide | Torsemide | 54 | 13 |
| Ondansetron Odt | Ondansetron | 53 | suppressed |
| Aripiprazole | Aripiprazole | 50 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 50 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 48 | 16 |
| Atenolol | Atenolol | 45 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | 13 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | suppressed |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Lovastatin | Lovastatin | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 21 |
| Linzess | Linaclotide | 39 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 17 |
| Bumetanide | Bumetanide | 38 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 37 | 13 |
| Finasteride | Finasteride | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Topiramate | Topiramate | 35 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Gemtesa | Vibegron | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Roflumilast | Roflumilast | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | 19 |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Epinephrine | Epinephrine | 19 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 13 |
| Risperidone | Risperidone | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $840.57 · 44 records | ABBVIE INC. | AREXVY, CAPLYTA, Cologuard Collection Kit, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Leqembi, MOUNJARO, OTEZLA, Ozempic, PROCLAIM, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error